I don't agree that the non compete should be "disliked" - trofinetide has to be developed for an indication to exclude Neuren from using NNZ2591 for that indication in the USA and this excludes the 4 indications already in play. Acadia only has rights to advance NNZ2591 for Retts and Fragile-X worldwide. Neuren has the rest worldwide and anything in the USA not targeted with trofinetide. Acadia can advance trofinetide for any indication but in reality - NNZ2591 is the superior drug and it is unlikely that Acadia will spend millions to advance trofinetide in an indication just to stymy Neuren with NNZ2591....
imho.
This is a stupendous deal for Neuren - that will have the same affect over the next few weeks/months that FDA approval did in late 2021 and early 2022 - imho.
I don't agree that the non compete should be "disliked" -...
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$14.96 |
Change
-0.170(1.12%) |
Mkt cap ! $1.912B | |||
| Open | High | Low | Value | Volume |
| $15.06 | $15.37 | $14.95 | $5.553M | 367.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 313 | $14.96 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.00 | 8746 | 3 |
View Market Depth
| Last trade - 16.10pm 02/10/2024 (20 minute delay) ? |
| NEU (ASX) Chart |